Does it excite you to optimize DMPK properties, and do you have hands-on experience with LC-MS bioanalysis of complex molecular formats? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague.
Zealand Pharma is significantly expanding its global R&D capabilities and establishing new research units in Cambridge, MA to advance diverse drug modality capabilities in metabolic disease. As part of this expansion, you will play a central role in the DMPK group, advancing LC-MS capabilities and DMPK science within complex molecular formats. This is a unique opportunity for a scientist with strong scientific curiosity and technical expertise across mass spectrometry, pharmacokinetics, drug metabolism and bioanalysis.
We offer exciting responsibilities:
You bring strong technical expertise across the full LC-MS bioanalysis and PK workflow, along with scientific curiosity and sound judgment. You enjoy working in a collaborative, multidisciplinary environment and are motivated to help shape a new platform and research center from an early stage. You communicate scientific data and concepts clearly and work effectively across cross-functional project teams.
You will join the Global DMPK department within Pharmacokinetics, Immunogenicity and Bioanalytical Sciences, working closely with cross-functional R&D stakeholders (e.g., Discovery, Translational, Toxicology, Clinical Pharmacology and Regulatory) to shape study strategies, interpret data, and communicate DMPK risks and recommendations.
We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture.
Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let’s bond and be bold.
Interested in bonding with us? Applications will be reviewed as they come in. While a cover letter is not required, please include a few sentences in your CV explaining your motivation for applying.
We are committed to an inclusive recruitment process and welcome applications from all job applicants.
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma-invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Cambridge, Massachusetts. Learn more at www.zealandpharma.com.
At Zealand Pharma, we are a Danish biotechnology company on a mission to change lives with next generation peptide medicines.
In our effort to reach our goals, bonding is at the core of everything we do. Let it be discovering and developing the best new peptide drugs for patients, engaging with partners or connecting with each other.
Ten drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market. Our current pipeline of internal product candidates focuses on obesity, chronic inflammation, and certain rare diseases.
Our leading obesity programs are backed by strong partners, including Roche and Boehringer Ingelheim.
We are based in Copenhagen (Søborg), Denmark, with a team in the U.S. For further information about our business and activities, please visit www.zealandpharma.com or bond with us through LinkedIn.
